While several clinical trials have already confirmed the effect of MGMT hypermethylation on chemotherapy resistance in gliomas [31] and glioblastomas [30,32], the MethMarker-optimized biomarker may facilitate the clinical confirmation of MGMT's predictive role in other cancers. This evidence concerns the gene MGMT and central nervous system cancer.